{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T04:13:28Z","timestamp":1795320808809,"version":"4.10.3"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.057","type":"journal-article","created":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T06:48:06Z","timestamp":1704610086000},"page":"573-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants"],"prefix":"10.1016","volume":"42","author":[{"given":"Mark H.","family":"Rozenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7698","authenticated-orcid":false,"given":"Liping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnna","family":"Perdrizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Cane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Arguedas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-2313","authenticated-orcid":false,"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-451X","authenticated-orcid":false,"given":"Maria J","family":"Tort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Dillon-Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Chilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond A.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.12.057_b0005","unstructured":"Advisory Committee on Immunization P. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-9): 1\u201335."},{"issue":"9","key":"10.1016\/j.vaccine.2023.12.057_b0010","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.057_b0020","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(37): 1174\u20131181.","DOI":"10.15585\/mmwr.mm7104a1"},{"issue":"25","key":"10.1016\/j.vaccine.2023.12.057_b0025","first-page":"521","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6\u201318 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.12.057_b0030","unstructured":"Centers for Disease Control and Prevention. Pneumococcal Disease: Surveillance and Reporting. https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html. Published 2020. Accessed 5 October, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0035","unstructured":"Grijalva CG, Griffin MR, Nuorti JP, Walter ND, Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine\u2014United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009; 58."},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2013.3924","article-title":"Trends in otitis media-related health care use in the United States, 2001\u20132011","volume":"168","author":"Marom","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0045","doi-asserted-by":"crossref","first-page":"e00309","DOI":"10.1128\/mBio.00309-10","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States","volume":"2","author":"Simonsen","year":"2011","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12913-018-3139-1","article-title":"Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"10.1016\/j.vaccine.2023.12.057_b0055","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid2706.204238","article-title":"Twenty-year public health impact of 7- and 13-valent pneumococcal conjugate vaccines in US children","volume":"27","author":"Wasserman","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.057_b0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijporl.2019.01.023","article-title":"National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States","volume":"119","author":"Zhou","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.057_b0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciaa917","article-title":"Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation","volume":"72","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.12.057_b0070","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0075","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0080","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cid\/cix310","article-title":"Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006\u20132014","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.12.057_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world","volume":"13","author":"Cui","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0090","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0095","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21645515.2015.1118593","article-title":"Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement","volume":"12","author":"Hausdorff","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.12.057_b0100","unstructured":"Pfizer. Prenar 20 (Pneumococcal 20-valent Conjugate Vaccine), suspension for intramuscular injection, prescribing information; June 2021."},{"issue":"33","key":"10.1016\/j.vaccine.2023.12.057_b0105","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.057_b0110","unstructured":"US Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers; 2020."},{"key":"10.1016\/j.vaccine.2023.12.057_b0115","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae; 2019. www.cdc.gov\/abcs\/downloads\/SPN_Surveillance_Report_2019.pdf. Published 2019. Accessed November 17, 2022."},{"issue":"48","key":"10.1016\/j.vaccine.2023.12.057_b0120","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","article-title":"Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States","volume":"28","author":"Rubin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.057_b0125","unstructured":"Stoecker C. Economic assessment of PCV15 &PCV20. Paper presented at: Advisory Committee on Immunization Practices Meeting. Atlanta, GA; 2021."},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.12.057_b0135","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2023.12.057_b0145","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2018. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu18.pdf. Published 2018. Accessed November 17, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0150","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae; 2017. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu17.pdf. Published 2017. Accessed November 17, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106476","article-title":"Mortality and readmission in the year following hospitalization for pneumonia among US adults","volume":"185","author":"Averin","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.vaccine.2023.12.057_b0160","unstructured":"US Census Bureau. National Demographic Analysis Tables; 2020. https:\/\/www.census.gov\/data\/tables\/2020\/demo\/popest\/2020-demographic-analysis-tables.html. Published 2021. Accessed November 17, 2022."},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.057_b0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2023.12.057_b0175","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2023.12.057_b0180","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.inf.0000232706.35674.2f","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs","volume":"25","author":"Hansen","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"29","key":"10.1016\/j.vaccine.2023.12.057_b0185","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.057_b0190","unstructured":"Pfizer. ABCs data (Data on File)."},{"key":"10.1016\/j.vaccine.2023.12.057_b0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12913-016-1432-4","article-title":"Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions","volume":"16","author":"Weycker","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41669-020-00240-9","article-title":"Attributable cost of adult hospitalized pneumonia beyond the acute phase","volume":"5","author":"Weycker","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.vaccine.2023.12.057_b0205","unstructured":"Centers for Disease Control and Prevention. CDC Vaccine Price List. https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html. Published 2023. Accessed November, 2023."},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0210","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1542\/peds.2012-3350","article-title":"Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine","volume":"132","author":"Stoecker","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0215","article-title":"Cost-effectiveness analysis of routine use of 15-valent pneumococcal conjugate vaccine in the US pediatric population","volume":"11","author":"Huang","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2023.12.057_b0220","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1542\/peds.2009-1542H","article-title":"Cost of vaccine administration among pediatric practices","volume":"124","author":"Glazner","year":"2009","journal-title":"Pediatrics"},{"issue":"18","key":"10.1016\/j.vaccine.2023.12.057_b0225","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.057_b0230","unstructured":"US Bureau of Labor Statistics. Average hours employed people spent working on days worked by day of week. https:\/\/www.bls.gov\/charts\/american-time-use\/emp-by-ftpt-job-edu-h.htm. Accessed November 29, 2022."},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40121-020-00294-6","article-title":"Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis","volume":"9","author":"Wilson","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0240","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijporl.2013.11.030","article-title":"Acute otitis media in young children - what do parents say?","volume":"78","author":"Barber","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.vaccine.2023.12.057_b0245","unstructured":"US Bureau of Labor Statistics. Civilian labor force participation rate. https:\/\/www.bls.gov\/charts\/employment-situation\/civilian-labor-force-participation-rate.htm. Accessed November 29, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0250","unstructured":"Organisation for Economic Co-operation and Development. Average wages. https:\/\/data.oecd.org\/earnwage\/average-wages.htm. Accessed November 29, 2022."},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.057_b0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples","volume":"30","author":"Jiang","year":"2021","journal-title":"Qual Life Res"},{"issue":"31\u201332","key":"10.1016\/j.vaccine.2023.12.057_b0260","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.057_b0265","doi-asserted-by":"crossref","first-page":"e6879","DOI":"10.1136\/bmj.e6879","article-title":"Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis","volume":"345","author":"Rozenbaum","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.12.057_b0270","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/1471-2334-13-597","article-title":"Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP","volume":"13","author":"Mangen","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.057_b0275","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","article-title":"The impact of community-acquired pneumonia on the health-related quality-of-life in elderly","volume":"17","author":"Mangen","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cid\/ciaa595","article-title":"One-year quality of life post-pneumonia diagnosis in Japanese adults","volume":"73","author":"Glick","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0285","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","article-title":"Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands","volume":"46","author":"Mangen","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2023.12.057_b0290","doi-asserted-by":"crossref","unstructured":"Oostenbrink R, HA AM, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55(8): 791\u201399.","DOI":"10.1016\/S0895-4356(02)00448-1"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0295","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/322587","article-title":"Complications of meningococcal disease in college students","volume":"33","author":"Erickson","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.057_b0300","unstructured":"Centers for Disease Control and Prevention. Guidance for Health Economics Studies Presented to the Advisory Committee on Immunization Practices (ACIP), 2019 Update. https:\/\/www.cdc.gov\/vaccines\/acip\/committee\/downloads\/Economics-Guidance-for-ACIP-2019.pdf. Published 2019. Accessed November 18, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0305","unstructured":"Centers for Disease Control and Prevention. Vaccination Coverage among Young Children (0 \u2013 35 Months). https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/childvaxview\/interactive-reports\/index.html. Published 2020. Accessed December 16, 2022."},{"key":"10.1016\/j.vaccine.2023.12.057_b0310","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.15585\/mmwr.mm7041a1","article-title":"Vaccination Coverage by Age 24 Months Among Children Born in 2017 and 2018 \u2014 National Immunization Survey-Child, United States, 2018\u20132020","volume":"70","author":"Hill","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.12.057_b0315","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15585\/mmwr.mm7202a3","article-title":"Vaccination Coverage by Age 24 Months Among Children Born During 2018\u20132019 \u2014 National Immunization Survey-Child, United States, 2019\u20132021","volume":"72","author":"Hill","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"10.1016\/j.vaccine.2023.12.057_b0320","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","article-title":"Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States","volume":"41","author":"Prasad","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.057_b0325","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jval.2022.10.006","article-title":"Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies","volume":"26","author":"Syeed","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.057_b0330","doi-asserted-by":"crossref","first-page":"2257426","DOI":"10.1080\/21645515.2023.2257426","article-title":"Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population","volume":"19","author":"Lytle","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.057_b0335","article-title":"Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants","volume":"11","author":"Warren","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2023.12.057_b0340","article-title":"Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom","volume":"11","author":"Wilson","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2023.12.057_b0345","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s40121-023-00828-8","article-title":"Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands","volume":"12","author":"Wilson","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2023.12.057_b0350","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core surveillance: Trends by Serotype Group. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu-types.html. Published 2018. Accessed November 17, 2022."},{"issue":"12","key":"10.1016\/j.vaccine.2023.12.057_b0355","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/ciu683","article-title":"Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent\/13-valent PCV","volume":"59","author":"Ben-Shimol","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.057_b0360","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/cid\/ciw347","article-title":"Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media","volume":"63","author":"Ben-Shimol","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2023.12.057_b0365","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1016\/j.vaccine.2015.08.022","article-title":"Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom","volume":"33","author":"Lau","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.12.057_b0370","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1473-3099(19)30297-X","article-title":"Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study","volume":"19","author":"Lo","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.12.057_b0375","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2023.12.057_b0380","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1016\/j.vaccine.2020.10.045","article-title":"Evaluating post-vaccine expansion patterns of pneumococcal serotypes","volume":"38","author":"Phillips","year":"2020","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23015037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23015037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:36:59Z","timestamp":1759405019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23015037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23015037"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}